Sun Pharma reports strong sales and earnings growth for 3rd-qtr
India’s largest drugmaker Sun Pharmaceutical Industries (BSE: 524715) has reported a strong set of financials for the fiscal year 2024 quarter ending December 31, 2023.
Highlights of the consolidated figures show that gross sales of 121,569 million rupees ($1.46 billion) grew 9.5%.
Earnings before interest, tax, depreciation and amortization (EBITDA) were 34,768 million rupees (including other operating revenues), increasing 15.8%. EBITDA margin for the quarter was 28.1% versus 26.7% during the like, year earlier quarter. Adjusted net profit (excluding the exceptional items) for third quarter FY24 was 25,936 million rupees, up 19.7%. Reported net profit for the period was 25,238 million rupees, 26% compared to 21,660 million rupees the year earlier.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze